POLBF (Poolbeg Pharma) Other Current Assets: $0.26 Mil (As of Dec. 2025)


What is Poolbeg Pharma Other Current Assets?

Poolbeg Pharma POLBF Other Current Assets is $0.26 Mil as of Dec. 2025. The stock has 1 warning sign investors should review.

Poolbeg Pharma's other current assets for the quarter that ended in Dec. 2025 was $0.26 Mil.

Poolbeg Pharma's quarterly other current assets increased from Dec. 2024 ($0.28 Mil) to Jun. 2025 ($0.38 Mil) but then declined from Jun. 2025 ($0.38 Mil) to Dec. 2025 ($0.26Mil).

Poolbeg Pharma's annual other current assets declined from Dec. 2023 ($0.79 Mil) to Dec. 2024 ($0.28 Mil) declined from Dec. 2024 ($0.28 Mil) to Dec. 2025 ($0.26 Mil).


Poolbeg Pharma Other Current Assets Related Terms


Poolbeg Pharma Other Current Assets Historical Data

* Premium members only.

The historical data trend for Poolbeg Pharma's Other Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Poolbeg Pharma Other Current Assets Chart

Poolbeg Pharma Annual Data
Trend Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Assets
0.06 0.10 0.79 0.28 0.26

Poolbeg Pharma Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Other Current Assets Get a 7-Day Free Trial Premium Member Only 0.79 0.29 0.28 0.38 0.26

Poolbeg Pharma Other Current Assets Calculation

Technically, the other current assets line may include any asset that will be used up within the next 12 months. However, other current assets never include assets that are listed elsewhere in the current assets section of the balance sheet. For this reason, other current assets are almost never:


Cash
Trade Receivables
Inventory

The assets grouped under other current assets are most commonly:


Prepaid Expenses
Tax Assets
Non-Trade Receivables
Other (too numerous to list)

Some companies can and do choose to report each of these items separately.

Other current assets may be made up largely of Prepaid Expenses - unless these are listed on a separate line of the balance sheet.

Prepaid expenses are exactly what they sound like. If a company pays a $30 million insurance premium on the last day of June that will provide coverage for the entire month of July, the company will record a $30 million prepaid expense to account for the insurance expense it will show in July that it already paid for in June.

Tax assets can be quite complex. It is not common for companies to have both tax assets and tax liabilities. It is important that investors take note of both items when considering future taxes.

Non-Trade receivables are rarely a large item. They include money owed to the company by non-customers. Non-trade receivables can be caused by related party transactions, the sale of a business unit, etc. The notes to the company's financial statements will often provide much more detail on this item if it is truly important.

There are a variety of other current assets like non-trade receivables which are simply too numerous to list. If a company is following correct reporting procedures, it should not lump items that are different from one another and yet individually important to the company together under the line Other Current Assets.

At most companies, other current assets are a small and unimportant part of the total balance sheet.

Frequently Asked Questions Learn more about Other Current Assets →
What does a Other Current Assets of $0.26 Mil mean?
Poolbeg Pharma (POLBF) has a Other Current Assets of $0.26 Mil as of Dec. 2025. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Poolbeg Pharma.
Is Poolbeg Pharma's Other Current Assets too high?
Poolbeg Pharma's current Other Current Assets is $0.26 Mil.
How does Poolbeg Pharma's Other Current Assets compare to VRTX and REGN?
Poolbeg Pharma's Other Current Assets of $0.26 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Assets for a Biotechnology company?
A good Other Current Assets depends on the Biotechnology industry context. However, Other Current Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Assets mean?
A high Other Current Assets can signal that a stock is expensive relative to its fundamentals. Other current assets as record on a company's balance sheet not categorized as standard assets. View historical data on Poolbeg Pharma. Poolbeg Pharma's current Other Current Assets is $0.26 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Poolbeg Pharma stock overvalued right now?
Poolbeg Pharma (POLBF) has a current Other Current Assets of $0.26 Mil. The current Other Current Assets is $0.26 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Assets calculated?
Other Current Assets is calculated from a company's financial statements. For Poolbeg Pharma (POLBF), the current Other Current Assets is $0.26 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Poolbeg Pharma Business Description

Other Exchanges POLB:UK7JN:Germany
Address 20 St. Andrew Street, The Clubhouse Holborn, London, GBR, EC4A 3AG
Poolbeg Pharma PLC is a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field. The Company's main asset, POLB 001, has the potential to expand administration of cancer immunotherapies from centralised specialist cancer centres into community hospitals by making the treatments safer through the prevention of the life-threatening side effect, Cytokine Release Syndrome (CRS). The group is also advancing the development of a patient-friendly therapy for obesity with an oral encapsulated GLP-1, offering a differentiated approach within one of the world's markets. It is focused on partnering its high-value programmes that are targeting large markets and addressing critical unmet medical needs.